Axios, a widely respected outlet known for its national reach and authoritative reporting on health and technology, profiled Prenosis and its FDA-authorized Sepsis ImmunoScore™, the groundbreaking AI-powered tool revolutionizing sepsis prediction and diagnosis with...
Prenosis Announces FDA De Novo Marketing Authorization of the Sepsis ImmunoScoreTM
The Sepsis ImmunoScoreTM is the first-ever AI Sepsis Diagnostic granted marketing authorization by the FDA. CHICAGO, April 3, 2024 /PRNewswire/ — Prenosis, Inc., an artificial intelligence company enabling precision medicine in acute care, today announced the...
Prenosis Inc. Appoints Leadership Team for Commercialization In Hospitals
AI health tech company—the world leader in data and insights for abnormal immune response in acute care—expands its executive team and adds additional sepsis clinical expert to its advisory board CHICAGO, Oct. 4, 2023 /PRNewswire/ — Prenosis, Inc., an artificial...
Prenosis Among Finalists Named for the 2022 Hearst Health Prize in Partnership With the UCLA Center for SMART Health
LOS ANGELES and SAN FRANCISCO, October 27, 2022 – The UCLA Center for SMART Health, an interdisciplinary collaborative that looks to the integrated transformation of healthcare through emergent data and technologies, and Hearst Health, a division of Hearst and leader...
Prenosis is a leader in Chicago, an emerging biotechnology hub–Crain’s
Crain’s Chicago Business, a highly regarded publication known for its in-depth reporting on business and innovation, features Prenosis CEO Bobby Reddy, Jr. in an article exploring Chicago’s emergence as a biotechnology hub. Reddy discusses Prenosis’ pivotal role...
Diagnostics firm adds investor to bring funding over $20M–MedCity
MedCity News, a trusted source for healthcare innovation and investment news, highlights Prenosis’ recent investment from PACE Healthcare Capital, advancing its mission to revolutionize sepsis care with AI-driven diagnostics and precision medicine solutions....
Prenosis Nabs Up to $4.3 Million From US DoD to Develop Early Sepsis POC Test–360Dx
360Dx, a leading source for clinical diagnostics news, highlights Prenosis’ milestone $4.3 million award from the US Department of Defense to advance sepsis detection technology for warfighters, reinforcing the transformative impact of its innovations in acute...
Prenosis, Roche Partner on Sepsis Detection–360Dx
360Dx, a leading publication covering innovations in clinical diagnostics, reports on Prenosis’ expanding collaboration with Roche Diagnostics, a significant step toward advancing sepsis detection and improving patient outcomes. The partnership aims to leverage...
Prenosis Aggregating Patient Biomarker, Clinical Data to Build a Better Sepsis Diagnostic–360Dx
360Dx, a leading publication focused on the clinical diagnostics industry, profiled Prenosis in its latest feature. The article explores how Prenosis is advancing precision medicine through its Sepsis ImmunoScore™, and its groundbreaking Immunix™ platform. 360Dx...
New Test Leverages Machine Learning to Diagnose and Predict Sepsis–MD+DI
MD+DI profiles Prenosis for its groundbreaking work in sepsis diagnostics. In this article CEO Bobby Reddy, Jr. highlights the immense global burden of sepsis, a condition responsible for more deaths worldwide than all cancers combined. Prenosis’ Immunix™ platform and...